Get started
Author

Conrad D. Oja

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
2018 · Matti Annala, Gillian Vandekerkhove, et al. · Cancer Discovery · 515
PDF
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
2019 · Daniel J Khalaf, Matti Annala, et al. · The Lancet Oncology · 360
Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer
2022 · Pamela J. Goodwin, Bingshu E. Chen, et al. · JAMA · 244
PDF
Effect of Metformin vs Placebo on and Metabolic Factors in NCIC CTG MA.32
2015 · P. J. Goodwin, W. R. Parulekar, et al. · JNCI Journal of the National Cancer Institute · 130
PDF
Influence of dose on liposome clearance: critical role of blood proteins
1996 · Conrad D. Oja, Sean C. Semple, et al. · Biochimica et Biophysica Acta (BBA) - Biomembranes · 119
PDF
Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition
2021 · Matti Annala, Sinja Taavitsainen, et al. · Clinical Cancer Research · 98
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial
2018 · Daniel J. Khalaf, Katherine Sunderland, et al. · European Urology · 74
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies
2020 · D.J. Khalaf, I.M. Aragón, et al. · Annals of Oncology · 46
A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).
2017 · Kim N. Chi, Matti Annala, et al. · Journal of Clinical Oncology · 36
Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCPRC): Results for 2nd-line therapy.
2018 · Daniel Khalaf, Matti Annala, et al. · Journal of Clinical Oncology · 28
Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
2016 · Sunil Parimi, Bernhard J. Eigl, et al. · Journal of Clinical Oncology · 14
A Lipid-based Delivery System for Antisense Oligonucleotides Derived from a Hydrophobic Complex
2002 · F.M.P. Wong, S.A. MacAdam, et al. · Journal of drug targeting · 12
Doxorubicin entrapped within liposome-associated antigens results in a selective inhibition of the antibody response to the linked antigen
2000 · Conrad Oja, Paul Tardi, et al. · Biochimica et Biophysica Acta (BBA) - Biomembranes · 12
PDF
Assessment of quality of life (QOL), cognitive function and depression in a randomized phase II study of abiraterone acetate (ABI) plus prednisone (P) vs enzalutamide (ENZA) for metastatic castrate-resistant prostate cancer (mCRPC).
2017 · Daniel Khalaf, Katherine Sunderland, et al. · Journal of Clinical Oncology · 10
Abstract GS1-08: CCTGMA.32, a phase III randomized double-blind placebo controlled adjuvant trial of metformin (MET) vs placebo (PLAC) in early breast cancer (BC): Results of the primary efficacy analysis (clinical trials.gov NCT01101438)
2022 · Pamela J. Goodwin, Bingshu E Chen, et al. · Cancer Research · 6
Genomic alterations in circulating tumor DNA (ctDNA) are associated with clinical outcomes in treatment-naive metastatic castration-resistant prostate cancer (mCRPC) patients commencing androgen receptor (AR)-targeted therapy
2016 · A.W. Wyatt, M. Annala, et al. · Annals of Oncology · 6
PDF
Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC).
2013 · Pamela Jean Goodwin, Wendy Parulekar, et al. · Journal of Clinical Oncology · 6
Circulating tumor DNA (ctDNA) and correlations with clinical prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC).
2017 · Daniel Khalaf, Matti Annala, et al. · Journal of Clinical Oncology · 3
Circulating tumor DNA (ctDNA) burden and actionable mutations in treatment-naïve metastatic castration-resistant prostate cancer (mCRPC).
2016 · Alexander William Wyatt, Matti Annala, et al. · Journal of Clinical Oncology · 2
HSD3B1 (1245A>C) polymorphism and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (AA) and enzalutamide (ENZA): Results from two prospective studies.
2020 · Isabel Aragon, Daniel Joseph Khalaf, et al. · Journal of Clinical Oncology · 1
Quality of life (QOL) for the treatment sequence of abiraterone acetate plus prednisone (AAP) followed by enzalutamide (ENZ) versus the opposite sequence for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized clinical trial.
2020 · Daniel J Khalaf, Katherine Sunderland, et al. · Journal of Clinical Oncology · 1
Immune system trickery and deception: Allograft-derived neuroendocrine carcinoma post kidney transplantation
2018 · Cyrus Chehroudi, Miles Mannas, et al. · Urology Case Reports · 1
PDF
Studies on Factors influencing the elimination of liposomes from the circulation
2009 · Oja, Conrad D. · Library and Archives Canada (Government of Canada) · 1
Figures S1-S18 from Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
2023 · Matti Annala, Gillian Vandekerkhove, et al.
PDF
Tables S1-S9 from Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
2023 · Matti Annala, Gillian Vandekerkhove, et al.
Works count: 84
Citation count: 1,725
H-index: 12
I10-index: 14
Year
Topic
Type